课题基金 / 基金详情

CONTINUOUS INFUSION PROLEUKIN (ALDESLEUKIN) CHIRON RECOMBINANT INTERLEUKIN

CONTINUOUS INFUSION PROLEUKIN (ALDESLEUKIN) CHIRON RECOMBINANT INTERLEUKIN
持续输注白介素原 (ALDESLEUKIN) CHIRON 重组白细胞介素
批准号：
6118381
负责人：
RONALD T. MITSUYASU
金额：
$2.51万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/6118381
关键词：
AIDS therapy HIV infections antiviral agents clinical research clinical trials combination chemotherapy dosage drug administration rate /duration drug screening /evaluation human subject human therapy evaluation immunotherapy injection /infusion interleukin 2 recombinant proteins

项目摘要

项目成果

RONALD T. MITSUYASU的其他基金

相似基金

相关文献

中文摘要
翻译
这项研究的主要目的是评估 持续输注重组人白介素2与抗逆转录病毒 HIV患者的治疗与单用抗逆转录病毒治疗的比较 感染和CD4计数在100-300个细胞/mm~3之间。安全和 白介素2的三个剂量方案的耐受性将是 评估以确定最佳方案，该方案可能是 对晚期长期应用IL-2有效 感染了艾滋病毒。
英文摘要
The primary objective of this study is to evaluate the effectiveness of continuous infusion recombitant interleukin-2(IL-2) with antiretroviral therapy compared to antiretroviral therapy alone in patients with HIV infection and CD4 counts between 100-300 cells/mm3. The safety and tolerance of the three dosing regiments of interleukin-2 will be evaluated in order to determine the optimal regimen which may be effective for long term administration of IL-2 in this advanced stage with HIV infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India
Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India
South American Prevention of HIV Research Training Program (SAPHIR)
South American Prevention of HIV Research Training Program (SAPHIR)
海外基金